Galapagos asthma deal with Bayer

12 June 2001

Galapagos Genomics NV, a Belgian functional genomics company, hasannounced a research collaboration with Bayer Yakuhin in Japan to identify the function of proteins encoded by newly-discovered genes involved in asthma.

Under the terms of the agreement, Bayer will provide Galapagos with a proprietary collection of human genes associated with asthma from which the latter will construct recombinant adenoviruses, using its PhenoSelect expression platform. Financial terms of the collaboration were not disclosed.

Onno van de Stolpe, Galapagos' chief executive, said the deal is the firm's first collaboration "with a top-tier pharmaceutical company and it is therefore an important milestone." He added that the deal "is an endorsement of our platform as an important tool in the rapid identification and validation of drug targets out of large gene collections."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight